Jones Financial Companies
CRSP icon

Jones Financial Companies’s CRISPR Therapeutics CRSP Stock Holding History

Jones Financial Companies’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.06M Buy
73,847
+10,181
+16% +$537K ﹤0.01% 1285
2026
Q1 		$2.91M Buy
63,666
+6,177
+11% +$326K ﹤0.01% 1278
2025
Q4 		$3.01M Buy
57,489
+12,774
+29% +$765K ﹤0.01% 815
2025
Q3 		$2.76M Buy
44,715
+14,948
+50% +$858K ﹤0.01% 764
2025
Q2 		$1.41M Buy
29,767
+8,828
+42% +$342K ﹤0.01% 870
2025
Q1 		$775K Buy
20,939
+9,678
+86% +$410K ﹤0.01% 959
2024
Q4 		$443K Buy
11,261
+5,022
+80% +$237K ﹤0.01% 1038
2024
Q3 		$295K Buy
6,239
+2,365
+61% +$120K ﹤0.01% 1005
2024
Q2 		$209K Buy
3,874
+2,709
+233% +$157K ﹤0.01% 822
2024
Q1 		$79.4K Buy
+1,165
New +$83.4K ﹤0.01% 639

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jones Financial Companies's CRSP Position: Q2 2026 in Review

Jones Financial Companies increased its CRISPR Therapeutics (CRSP) stake by 16% in Q2 2026, buying an estimated $537K and bringing the position to 73,847 shares worth $4.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1285.

Jones Financial Companies first reported a position in CRSP in Q1 2024 and has held it in 10 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Jones Financial Companies held 73,847 shares of CRISPR Therapeutics worth $4.06M as of Q2 2026.
  • Jones Financial Companies bought 10,181 CRISPR Therapeutics shares in Q2 2026, an estimated $537K.
  • CRISPR Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #1285 holding.
  • Jones Financial Companies first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.